Glenmark Pharmaceuticals Ltd (GLENMARK) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Mid Cap

Glenmark Pharma Share Price

1,965.75 -8.40 -0.43%
as on 05-Dec'25 16:59

Glenmark Pharmaceuticals Ltd (GLENMARK) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Glenmark Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Glenmark Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
55.17
Market Cap:
55,710.7 Cr.
52-wk low:
1,274.7
52-wk high:
2,286.2

Is Glenmark Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Glenmark Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glenmark Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 18.5%20.5%14.8%16.5%14%15.3%14.2%4.4%4.9%16.2%-
Value Creation
Index
0.70.80.10.20.00.10.1-0.7-0.60.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7,5629,0799,0749,86510,64110,94412,30511,58311,81313,32215,585
Sales YoY Gr.-20.1%-0.1%8.7%7.9%2.9%12.4%-5.9%2%12.8%-
Adj EPS 26.74326.824.223.335.137.87.8-4545.735.8
YoY Gr.-60.7%-37.6%-9.7%-3.8%50.8%7.7%-79.4%-677.4%NA-
BVPS (₹) 128.6159.2182.6198.3214.7249.6321.5335.1277.5313.3339.5
Adj Net
Profit
7541,2127576836579911,067220-1,2691,2881,010
Cash Flow from Ops. 3456571,6481,3241,3921,1311,109625-265-828-
Debt/CF from Ops. 11.67.22.83.43.54.13.37-3.7-2.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.5%4.6%2.7%12.8%
Adj EPS 6.1%14.4%6.5%NA
BVPS10.4%7.9%-0.9%12.9%
Share Price 7.5% 31.3% 65.3% 27.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
27.929.915.712.711.315.113.22.4-14.715.411
Op. Profit
Mgn %
19.223.217.816.11619.718.914.110.117.726.3
Net Profit
Mgn %
1013.48.36.96.29.19.12.6-10.29.76.5
Debt to
Equity
1.11.10.90.80.80.70.40.50.10.30.1
Working Cap
Days
2422192362172018888948886108
Cash Conv.
Cycle
6069826656-28-21-4-14-2540

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Glenmark Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 5.4 35.8
TTM Sales (₹ Cr.) 7,517 15,585
BVPS (₹.) 848.3 339.5
Reserves (₹ Cr.) 23,911 9,554
P/BV 2.33 5.81
PE 365.08 55.17
From the Market
52 Week Low / High (₹) 1274.70 / 2286.15
All Time Low / High (₹) 1.89 / 2286.15
Market Cap (₹ Cr.) 55,711
Equity (₹ Cr.) 28.2
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Glenmark Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Glenmark Pharma - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Glenmark Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales7,5629,0799,0749,86510,64110,94412,30511,58311,81313,322
Operating Expenses 6,1257,0437,4598,2808,9438,8609,9859,94810,61810,970
Manufacturing Costs6246747868908438039857451,1371,119
Material Costs2,2472,5522,9633,2843,6243,6204,3124,2044,3524,287
Employee Cost 1,3781,6411,8722,0562,2552,3442,4472,6012,8683,022
Other Costs 1,8762,1761,8382,0492,2212,0922,2402,3982,2612,542
Operating Profit 1,4372,0371,6151,5861,6982,0842,3201,6351,1952,351
Operating Profit Margin (%) 19.0%22.4%17.8%16.1%16.0%19.0%18.9%14.1%10.1%17.7%
Other Income 20379120816050167289840114
Interest 179237286335377353298349516207
Depreciation 234264302326417444487569582486
Exceptional Items 0-8101673345-261-766-901-373
Profit Before Tax 1,0441,4911,1191,3011,0961,3821,441240361,399
Tax 3013833153763204124483291,867352
Profit After Tax 7431,109804925776970994-90-1,8311,047
PAT Margin (%) 9.8%12.2%8.9%9.4%7.3%8.9%8.1%-0.8%-15.5%7.9%
Adjusted EPS (₹)26.339.328.532.827.534.433.410.5-53.237.1
Dividend Payout Ratio (%)8%5%7%6%9%7%7%24%-5%7%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3,6284,4915,1535,5956,0577,0439,0709,4567,8308,840
Share Capital 28282828282828282828
Reserves 3,6004,4635,1255,5666,0297,0159,0429,4287,8018,812
Minority Interest-0-0-0-0-0-0351365-0-0
Debt3,2754,7244,4373,8774,4864,4022,9424,2028332,194
Long Term Debt2,4874,5364,1423,5744,0433,8892,5723,8520513
Short Term Debt7871872953034435133703508331,681
Trade Payables1,9411,7431,8702,2212,1262,2382,2892,0002,5362,580
Others Liabilities 285-505-1842145613877451,5422,1101,312
Total Liabilities 9,12810,45311,27511,90613,22914,06915,39717,56613,30914,925

Fixed Assets

Gross Block4,3014,7705,3686,5278,2708,73210,21310,3609,62010,365
Accumulated Depreciation1,7072,0152,3382,8573,2413,6034,3264,9385,4095,878
Net Fixed Assets 2,5942,7553,0303,6705,0295,1295,8875,4224,2104,487
CWIP 5437081,1221,3991,2221,3821,0101,190662835
Investments 171615302525504579056
Inventories1,5682,1392,0312,2522,1362,2772,5002,3742,5133,029
Trade Receivables2,4932,4042,3322,1952,4092,5723,1013,6651,8583,342
Cash Equivalents 8571,0581,2359381,1111,1391,4121,1601,6591,705
Others Assets 1,0571,3731,5121,4231,2981,5461,4383,7111,6161,472
Total Assets 9,12810,45311,27511,90613,22914,06915,39717,56613,30914,925

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 3456571,6481,3241,3921,1311,109625-265-828
PBT 1,0441,4911,1191,3011,0961,3821,4418685691,399
Adjustment 3917275713306366457871,4721,010982
Changes in Working Capital -612-862309136127-386-561-1074-797-2529
Tax Paid -478-699-352-443-467-510-558-641-1,047-680
Cash Flow From Investing Activity -880-712-1,013-699-784-675-333-5284,5612
Capex -889-733-1,023-610-775-675-358-551-896-747
Net Investments 000-1550-10-17-37
Others 8219-74-13035235,450786
Cash Flow From Financing Activity 699543-468-739-445-442-520-77-3,906787
Net Proceeds from Shares 935000000010
Net Proceeds from Borrowing -4411,400-290-381-116-67-889650-3,649367
Interest Paid -180-184-213-270-301-294-251-312-517-191
Dividend Paid -68-68-68-68-69-70-93-137-118-70
Others 452-606102-2041-11712-279377682
Net Cash Flow 163488166-1141641425519389-38

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)27.4627.3116.6717.2113.3214.8112.33-0.97-21.1812.56
ROCE (%)18.5320.5414.7716.4714.0415.314.194.434.8816.16
Asset Turnover Ratio0.880.940.840.850.851.851.891.711.792.08
PAT to CFO Conversion(x)0.460.592.051.431.791.171.12N/AN/A-0.79
Working Capital Days
Receivable Days119979584793637443632
Inventory Days68748479753231323234
Payable Days310263222227219220192186190218

Glenmark Pharmaceuticals Ltd Stock News

Glenmark Pharmaceuticals Ltd FAQs

The current trading price of Glenmark Pharma on 05-Dec-2025 16:59 is ₹1,965.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Glenmark Pharma stood at ₹55,710.7.
The latest P/E ratio of Glenmark Pharma as of 04-Dec-2025 is 365.1.
The latest P/B ratio of Glenmark Pharma as of 04-Dec-2025 is 2.33.
The 52-week high of Glenmark Pharma is ₹2,286.2 and the 52-week low is ₹1,274.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glenmark Pharma is ₹7,517 ( Cr.) .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals (GPL) was incorporated in 1977. It is global pharmaceutical company headquartered in Mumbai, India. Glenmark Pharmaceuticals’ portfolio spans branded generics, speciality, generics, and OTC products, built on deep therapeutic expertise and a strong commercial presence across various counties. With world-class manufacturing sites and cutting-edge R&D centres, the company delivers high-quality, accessible medicines across categories and geographies, consistently upholding the highest standards of quality, compliance, and supply reliability. 

The company has worked towards improving the lives of patients globally. In the pursuit of this mission, Glenmark has focused on building a global Innovative/Specialty, Generics and OTC business in the therapy areas of Dermatology, Respiratory and Oncology. It also has strong regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Glenmark is driven by a continuous commitment to create ‘A New Way for a New World’. Harnessing the potential of its core strengths of innovation, research, and scientific knowledge, the company remain determined to consistently challenge established treatment paradigms. It allows it to identify and deliver promising solutions that make a considerable difference to the lives of patients in diverse geographies. 

Business area of the company

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products.

The company’s therapy areas

  • Dermatology: Glenmark is one of the leaders in dermatology in India, with a wide range of product offerings that serve diverse therapeutic areas in skin care.
  • Respiratory: Its respiratory portfolio provides holistic disease management solutions from simple and acute ailments like cough and allergic rhinitis to the more complex and chronic ailments like asthma and COPD (Chronic Obstructive Pulmonary Disease). The company offers class leading products like Ascoril range of products.
  • Cardiology: Long ago, Glenmark entered antihypertensive segment in Indian pharmaceutical market. Now, the company is leader in the segment and have introduced several new variants to bring radical shift in the management of blood pressure.
  • Diabetes: Glenmark embarked on a journey to manage Diabetes and complications associated with it. The introduction and success of Metformin paved the way for it to establish itself as a significant player in the treatment and control of Diabetes.
  • Oncology: Glenmark Oncology launched products in the areas of supportive cancer care, prostate cancer, breast cancer, lung cancer and the hematological malignancies.
  • Anti-Infectives: The company has a wide range of high quality & affordable anti-infectives to improve patient care and meet the growing needs of the Indian population.
Awards

  • 2011: SCRIP crowned Glenmark as the ‘Best Pharma Company in Emerging markets’ and ‘Best Overall Pipline’ at SCRIP Awards 2011 in London.
  • 2012: Swiss Ambassador's award for Exceptional Innovation - 2012.
  • 2014: It received the Bombay Chamber of Commerce and Industry Civic Award 2014.
  • 2015: It was conferred with the Pharmaexcil Gold Award for New Chemical Entities 2015.
  • 2015: It was conferred with the prestigious Golden Peacock Management Award - 2015 for its Environment Sustainability initiatives at the Goa manufacturing facility.
  • 2019: Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row.
  • 2020: Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the third year in a row.
  • 2021: Glenmark’s Goa plant has won this award for the second consecutive year, with highest scores for 2021 as well as 2020. The British Safety Council, through this award, recognizes organizations that have demonstrated commitment to occupational health, safety and well-being across the globe.
  • 2021: The Apex India Green Leaf Awards 2021 conferred by the Apex Foundation of India recognizing Glenmark sites for its dedicated efforts toward environmental initiatives and sustainable development.
  • 2022: Glenmark was recognized for its efforts during the pandemic for supporting COVID frontline workers by providing them meals under the program, ‘Feed the front liners’, Southeast Asia category for the year 2021, by ‘Global Brands Magazine’.
  • 2022: Glenmark was declared a winner at the 5th Annual Health Safety Environment Strategy Summit & Awards 2022 in the category – ‘Managing Risks and Risk Assessment at Work’.
  • 2022: India Pharma and India Medical Device Awards 2022 conferred by the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India to recognizes Glenmark’s multiple patents and commercialized innovations over the past three years.
  • 2023: Glenmark won a Gold Award for being a Popular Medical Brand of the year; and a Silver Award for the Innovative Manufacturer of the Year. These awards recognize its dedication to enriching lives through innovative solutions globally.
  • 2023: Glenmark Foundation has been honoured with the ‘Foundation of the Year’ award at the 7th Edition Corporate Social Responsibility Summit & Awards 2023. 
  • 2023: Glenmark has been honoured with the prestigious ‘Sustainable Organization Award 2023’ at Sustainability Summit & Awards powered by UBS Forums.
  • 2023: Glenmark won 2 accolades at the Business World Sustainable Conclave for being among the most sustainable companies in India for the year 2022-23.
  • 2023: Glenmark has been honoured with an esteemed award at The Economic Times Sustainable Organisations 2023 for its Valuable Sustainability Initiatives.
  • 2024: Glenmark Pharmaceuticals Goa Manufacturing Units won the Platinum Award for Outstanding Achievement in Occupational Health and Safety conferred by the Sustainable Development Foundation, a Unit of ‘Ek Kaam Desh Ke Naam’.
  • 2025: Glenmark Pharmaceuticals Sp. z o.o. was awarded the HR Quality Award by the Polish HR Association as part of the HR Quality Certification 2025 program.
  • 2025: Glenmark was awarded “Pharma Company of the Year” under Large category at the FE Pharma Summit and Awards 2025.

Milestone

  • 1977: Mr. Gracias Saldanha (Founder Emeritus) laid the foundation stone of Glenmark.
  • 1979: Forayed into Dermatology therapy with the launch of ‘Candid Cream’.
  • 1980: Commenced operations in Russia and CIS.
  • 1983: Commissioned first manufacturing unit in Nashik.
  • 1987: Entered the Respiratory segment with the launch of Ascoril, a cough expectorant.
  • 1999: Set up its first Research and Development center at Sinnar.
  • 2000: Went public with a market capitalization of USD 40 Mn on the Indian bourses, NSE & BSE
  • 2000: Set up a second R&D center at Mahape, Navi Mumbai, to focus on Novel Chemical Entities
  • 2001: Commenced production of APIs at the Kurkumbh API manufacturing facility in Maharashtra.
  • 2002: Acquired API manufacturing plants at Ankleshwar, Gujarat.
  • 2003: Established North American subsidiary, Glenmark Pharmaceuticals, Inc.
  • 2004: Entered the European market through Glenmark Pharmaceuticals Europe.
  • 2005: Launched front-end commercial sales with first generic product in the U.S. 
  • 2005: Set up its first manufacturing facility built to the U.S. FDA specifications in Goa, India Struck its second out-licensing deal for Oglemilast (GRC 3886) with Teijin Pharma, Japan for USD 6 Mn (upfront payment).
  • 2006: Made debut in the Oncology segment with the launch of Aprecap (Aprepitant capsules) in India.
  • 2006: Established first R&D Center for New Biological Entities research in Switzerland
  • 2007: Entered the Central Eastern Europe market with the acquisition of Medicamenta, a Czech based pharmaceutical Company.
  • 2009: Commissioned the third R&D center in Taloja, Maharashtra, India
  • 2010: Out-licensed GRC 15300, a first-in-class TRPV3 antagonist, to Sanofi-Aventis for USD 25 Mn (upfront payment).
  • 2011: Out-licensed first New Biological Entity, GBR 500, to Sanofi-Aventis for USD 55 Mn (upfront and milestone payments).
  • 2012: Out-licensed mPEGS-1 Inhibitor to Forest Labs for USD 15 Mn (upfront payment)
  • 2014: Commissioned a new manufacturing facility for injectables and oral solids in Monroe, North Carolina, U.S.
  • 2014: Established a new antibody manufacturing facility to provide clinical GMP-grade biologics for clinical trials in La Chaux-deFonds, Switzerland.
  • 2015: Grew Respiratory portfolio, entered into an agreement with Celon, Poland for generic Seretide Accuhaler in Europe and received approval for generic version in Russia.
  • 2016: Launched differentiated generics, and introduced Ezetimibe, the generic version of Zetia in the U.S.
  • 2018: Signed an exclusive licensing agreement with Harbour Biomed in Greater China to develop, manufacture and commercialize GBR 1302.
  • 2019: Spun out its API arm, Glenmark Life Sciences (GLS) Created an innovation subsidiary focusing on immuno-oncology, Ichnos Sciences, Inc. (Ichnos).
  • 2020: Launched FabiFlu (Favipiravir) for mild to moderate COVID-19; exported to 24 countries by June 2021.
  • 2021: Ichnos outlicensed its IL-1RAP antagonist, ISB 880, to Almirall SA for an upfront payment of EUR 20.8 Mn.
  • 2022: The U.S. FDA approved Ryaltris, first global branded specialty drug for treating symptoms of seasonal allergic rhinitis.
  • 2022: Became the first Indian pharmaceutical Company to raise a Sustainability-Linked Loan (SLL).
  • 2023: Announced proposed divestment of majority stake in GLS.  Agreed to divest 75% stake in GLS to Nirma Limited.
  • 2023: Announced partnership with Cosmo for Winlevi in Europe and South Africa.
  • 2024: Glenmark and Ichnos announced ‘Ichnos Glenmark Innovation’ (IGI) alliance to accelerate new drug discovery in cancer treatment.
  • 2024: Partnered with Pfizer to launch Abrocitinib in India under the brand name Jabryus.
  • 2024: Completed divestment of 75% stake in GLS to Nirma.
  • 2025: Launched TEVIMBRA and Brukinsa in India for treatment of NSCLC and hematological malignancies respectively.
  • 2025: Ryaltris was launched in more than 11 markets in FY 2025 and is now commercialized in 44 markets globally.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×